The development of tailor-made immunotherapy based on ovarian cancer local immunity analysis
Project/Area Number |
15K10714
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Fujita Health University (2017) Nagoya University (2015-2016) |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
梶山 広明 名古屋大学, 医学系研究科, 准教授 (00345886)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 腹膜播種 / 癌微小環境 / サイトカイン / 卵巣癌 / 微小環境 / IL-33 / 免疫療法 / 癌免疫療法 |
Outline of Final Research Achievements |
We aimed to determine the role of cancer-associated mesothelial cells (CAMCs) in the promotion of tumor neovascularization and vascular permeability via enhanced VEGF production and loclal immunologic effects. We examined whether a characteristic morphological change in human peritoneal mesothelial cells (HPMCs) was observed in the presence of malignant ascites and tumor-derived TGF-β. We focused on the enhanced production of VEGF in CAMCs and its crucial role in endothelial tube formation. We found that EOC-derived TGF-β induced typical EMT-like morphological alteration in HPMCs, which was associated with CAMCs. We further discovered that CAMCs play a crucial role in the enhanced VEGF production.Furethermore we showed that IL-33 secretion was elevated in high metastatic cell lines.The novel mechanism of CAMCs as a facilitator of EOC progression and immnunological effect are displayed by microenvironmental cell-to-cell communication.
|
Report
(4 results)
Research Products
(4 results)